Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ipatasertib is an orally active, potent and selective Akt inhibitor with antitumor activity. Inhibition of Akt activity by Ipatasertib resulted in blockade of cell-cycle progression and reduced viability of cancer cell lines. Markers of Akt activation, including high-basal phospho-Akt levels, PTEN loss, and PIK3CA kinase domain mutations, correlate with sensitivity to Ipatasertib.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | Ipatasertib is an orally active, potent and selective Akt inhibitor with antitumor activity. Inhibition of Akt activity by Ipatasertib resulted in blockade of cell-cycle progression and reduced viability of cancer cell lines. Markers of Akt activation, including high-basal phospho-Akt levels, PTEN loss, and PIK3CA kinase domain mutations, correlate with sensitivity to Ipatasertib. |
Synonyms | GDC0068, RG 7440, GDC 0068, RG-7440, GDC-0068, RG7440 |
Molecular Weight | 494.46 |
Formula | C24H33Cl2N5O2 |
CAS No. | 1489263-16-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ipatasertib HCl 1489263-16-2 GDC0068 RG 7440 GDC 0068 RG-7440 GDC-0068 RG7440 inhibitor inhibit